Late, or delayed, restenosis does not present a clinical concern after drug-eluting stent (DES) implantation, according to Patrick Serruys, MD, professor of interventional cardiology at the Interuniversity Cardiological Institute of The Netherlands and Erasmus University. Serruys presented his “Late (or Delayed) Restenosis” lecture Sunday at the DES Summit during the Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C.
He based his arguments on:
- Evidence based on sequential IVUS studies
- Evidence based on the longest studies
- Target lesion restenosis in bare metal stents (BMS) increases after four years of implantation – 15 percent at one year, 17 percent at three years and 8 percent at four years.
- Evidence based on the most recent studies, including multi-center registry trials and meta-analysis trials
- Evidence based on mono-center registries
- Target vessel restenosis up to four years remains 5 percent.
- Evidence based on re-intervention needs
- Any re-intervention up to three years in stents is 85.5 percent in DES and 73.3 percent in BMS.